Methylation-based Discovery Platform

About CH3 BioSystems

CH3 BioSystems is a private, early-revenue biotechnology company founded in 2015, specializing in synthetic biology and metabolic research tools centered on epigenetic regulation, specifically protein methylation. The company operates a hybrid business model, selling proprietary research reagents (like its flagship ANTI-mRG antibody) and cell lines directly to academic and corporate researchers while pursuing a long-term vision of discovering novel drug and diagnostic candidates. Its strategy is to use its platform to first serve the research tools market, generating revenue and validating its technology, to ultimately identify and commercialize its own therapeutic programs. Leadership consists of scientific co-founders, indicating a strong research-driven culture.

Therapeutic Areas